Roflumilast for COPD

Drugs of Today

Volumn 46, Issue 11, 2010, Pages 823-831

  Izquierdo Alonso, José Luis ^a   Aparicio, J ^b  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b Medical Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLIC AMP; GLUCOCORTICOID; LONG ACTING BETA 1 ADRENOCEPTOR AGONIST; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PLACEBO; ROFLUMILAST; ROFLUMILAST N OXIDE; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR;

ADD ON THERAPY; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG PARENCHYMA; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MONOCYTE; NAUSEA; NEUTROPHIL; NONHUMAN; PHARMACODYNAMICS; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; VASODILATATION; WEIGHT REDUCTION; ANIMAL; DRUG COMBINATION; PATHOPHYSIOLOGY;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; CYCLOPROPANES; DRUG THERAPY, COMBINATION; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 79955921539     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.11.521831     Document Type: Review

References (38)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. www.goldcopd.com.
2. Soler-Cataluña, J.J., Martínez-García, M.A., Román Sánchez, P., Salcedo, E., Navarro, M., Ochando, R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60(11): 925-31.
3. Sobradillo Pena, V., Miravitlles, M., Gabriel, R. et al. Geographic variations in prevalence and underdiagnosis of COPD: Results of the IBERPOC multicentre epidemiological study. Chest 2000, 118(4): 981-9.
4. Menezes, A.M., Perez-Padilla, R., Jardim, J.R. et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): A prevalence study. Lancet 2005, 366(9500): 1875-81.
5. Buist, A.S., McBurnie, M.A., Vollmer, W.M. et al. International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. Lancet 2007, 370(9589): 741-50.
6. Celli, B.R., MacNee, W.; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6): 932-46.
7. Muller, T., Engels, P., Fozard, J.R. Subtypes of the type 4 cAMP phosphodiesterases: Structure, regulation and selective inhibition. Trends Pharmacol Sci 1996, 17(8): 294-8. (Pubitemid 26261894)
8. Hatzelmann, A., Schudt, C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001, 297(1): 267-79.
9. Hatzelmann, A., Morcillo, E.J., Lungarella, G. et al. The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010, 23(4): 235-56.
10. Cosio, M.G., Saetta, M., Agusti, A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009, 360(23): 2445-54.
11. Sanz, M.J., Cortijo, J., Morcillo, E.J. PDE4 inhibitors as new anti-inflammatory drugs: Effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther 2005, 106(3): 269-97.
12. Grootendorst, D.C., Gauw, S.A., Verhoosel, R.M. et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007, 62(12): 1081-7.
13. Keatings, V.M., Jatakanon, A., Worsdell, Y.M., Barnes, P.J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997, 155(2): 542-8.
14. Bethke, T.D., Bohmer, G.M., Hermann, R. et al. Dose proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 2007, 47(1): 26-36.
15. Calverley, P., Pauwels, R., Vestbo, J. et al.; TRial of Inhaled Steroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003, 361(9356): 449-56.
16. Casaburi, R., Mahler, D.A., Jones, P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19(2): 217-24.
17. Donohue, J.F., van Noord, J.A., Bateman, E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002, 122(1): 47-55.
18. Szafranski, W., Cukier, A., Ramirez, A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21(1): 74-81.
19. Calverley, P.M., Sanchez-Toril, F., McIvor, A., Teichmann, P., Bredenbroeker, D., Fabbri, L.M. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176(2): 154-61.
20. Calverley, P.M., Rabe, K.F., Goehring, U.M., Kristiansen, S., Fabbri, L.M., Martinez, F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials. Lancet 2009, 374(9691): 685-94.
21. Fabbri, L.M., Calverley, P., Izquierdo, J.L. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: Two randomised clinical trials. Lancet 2009, 374(9691): 695-703.
22. Bredenbröker, D., Syed, J., Leichtl, S., Rathgeb, F., Wurst, W. Safety of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in patients with COPD. Am J Respir Crit Care Med 2002, 165(7, Suppl.): Abst 595.
23. Bredenbröker, D., Syed, J., Leichtl, S., Rathgeb, F., Wurst, W. Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease. Eur Respir J 2002, (Suppl. 38): Abst 2330.
24. Leichtl, S., Syed, J., Bredenbröker, D., Rahtgeb, F., Wurst, W. Efficacy of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 165(7, Suppl.): Abst 229.
25. Leichtl, S., Syed, J., Bredenbröker, D., Rahtgeb, F., Wurst, W. Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 165(7, Suppl.): A229.
26. Schmid-Wirlitsch, C., Braman, S.S., Hubbard, R.C., Bredenbroeker, D., Bethke, T.D. Efficacy and safety of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in COPD. US COPD Coalition, National COPD Conference, On-Site Program Book 2003, 67.
27. Bredenbröker, D., Hubbard, R.C., Schmid-Wirlitsch, C., Bethke, T.D. Long-term safety and tolerability of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in COPD. US COPD Coalition, National COPD Conference, On-Site Program Book 2003, 67.
28. Van Noord, J.A., Bateman, E.D., Steffen, H., Timar, M., Schmid-Wirlitsch, C., Bredenbroeker, D., Bethke, T.D. Longterm safety of roflumilast in the treatment of chronic obstructive pulmonary disease. Chest 2004, 126(4, Suppl.): Abst 805S.
29. Boszormenyi-Nagy, G., Pieters, W.R., Steffen, H., Timar, M., Vinkler, I., Teichmann, P., Bredenbroeker, D. The effect of roflumilast treatment and subsequent withdrawal in patients with COPD. Proc Am Thorac Soc 2005, 2(Abstracts Issue): A544.
30. Bateman, E.D., Holmes, M., Muir, J.F., Andrae, K., Witte, S., Bredenbroeker, D. Safety profile of roflumilast, a novel, selective phosphodiesterase 4 inhibitor, in patients with moderate to severe COPD. Am J Respir Crit Care Med 2004, 169(7, Suppl.): A596.
31. O'Donnell, D., Muir, J.F., Jenkins, C., Plit, M., Brockhaus, F., Witte, S., Bredenbroeker, D. Roflumilast, a novel, selective phosphodiesterase 4 inhibitor, improves quality of life and lowers exacerbation rate in patients with moderate to severe COPD. Am J Respir Crit Care Med 2004, 169(7, Suppl.): A602.
32. O'Donnell, D., Rabe, K.F., Jenkins, C., Muir, J.F., Witte, S., Bredenbröker, D. FEV1: A useful outcome measure of lung function in COPD as assessed in a large clinical study with roflumilast. Eur Respir J 2004, 24(Suppl. 48): Abst 342.
33. Rabe, K.F., Bateman, E.D., O'Donnell, D., Witte, S., Bredenbroker, D., Bethke, T.D. Roflumilast - An oral antiinflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2005, 366(9485): 563-71.
34. Rabe, K.F., O'Donnell, D., Corey, R., Andrae, K., Witte, S. Efficacy and safety of roflumilast in a large COPD study. 11th Conf Eur Soc Gen Pract Family Med (Sept 3-7, Kos Island) 2005, Abst.
35. Rabe, K.F., O'Donnell, D., Adler, L. et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor improves lung function and quality of life in patients with COPD. COPD Cong (June 9-11, Birmingham) 2004, Abst.
36. Rabe, K.F., O'Donnell, D., Muir, J.F., Jenkins, C., Witte, S., Bredenbröker, D., Bethke, T.D. Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD. Eur Respir J 2004, 24(Suppl. 48): Abst 267.
37. Rabe, K.F., O'Donnell, D., Bateman, E.D., Andrae, K., Witte, S., Bredenbroeker, D. Roflumilast improves lung function and quality of life in chronic obstructive pulmonary disease. Chest 2004, 126(4, Suppl.): Abst 709S.
38. Rabe, K.F., Chapman, K.R., Joubert, J., Vetter, N., Witte, S., Bredenbroeker, D. Roflumilast, a novel, selective phosphodiesterase 4 inhibitor, improves lung function in patients with moderate to severe COPD. Am J Respir Crit Care Med 2004, 169(7, Suppl.): A518.